The overall percent agreement for ctDNA and tumour samples to detect BRCA1/2 and HRR mutations was 94.8% (95% CI: 91.9–97.8) and 91.5% (95% CI: 87.8–95.3), respectively (Additional file 2: Table S12). This evidence concerns the gene BRCA1 and neoplasm.